Accumulating evidence indicates that FLNA dysregulation is implicated in various cancer types, including breast cancer (Xu et al., 2010), parathyroid carcinoma (Storvall et al., 2021), adrenocortical carcinoma (Esposito et al., 2025), and prostate cancer (Di Donato et al., 2021). This evidence concerns the gene FLNA and adrenal cortex carcinoma.